Audit: QRS - Sodium Citrate for Health & Longevity
Audit conducted on 27/08/2026 04:23 using AI4L / Opus 5
Iterations
Summary
| Items |
Count |
| Total |
93 |
| Passed |
85 |
| Failed |
0 |
| N/A |
8 |
| Pass Rate |
100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # |
Description |
Result |
Comments |
| 1.1 |
Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. |
🟢 |
|
| 1.2 |
Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. |
🟢 |
|
| 1.3 |
The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). |
🟢 |
|
| 1.4 |
The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. |
🟢 |
|
| 1.5 |
PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. |
🟢 |
No PMIDs, NCT IDs, study citations, expert names or brand names appear anywhere in the QRS. |
| 1.6 |
The QRS does not introduce new attributions. |
🟢 |
|
2. Focus, Tone & Audience
| # |
Description |
Result |
Comments |
| 2.1 |
The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. |
🟢 |
|
| 2.2 |
The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging |
🟢 |
|
| 2.3 |
The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor |
🟢 |
|
| 2.4 |
The QRS avoids language that implies medical or clinical advice |
🟢 |
|
| 2.5 |
The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” |
🟢 |
|
| 2.6 |
The QRS never addresses “the reader” directly — it presents evidence, not guidance |
🟢 |
|
| 2.7 |
The QRS is written in plain language, avoiding unnecessary medical jargon |
🟢 |
|
| 2.8 |
Information is presented in a concise and very compact manner |
🟢 |
|
| 2.9 |
It DOES NOT address the reader directly |
🟢 |
|
| 2.10 |
The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. |
🟢 |
|
| 2.11 |
The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. |
🟢 |
|
| 2.12 |
The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. |
🟢 |
|
| 2.13 |
Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. |
🟢 |
|
| 2.14 |
The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. |
🟢 |
|
| 2.15 |
The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. |
🟢 |
|
3. Template Integrity
| # |
Description |
Result |
Comments |
| 3.1 |
The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 |
|
| 3.2 |
All “…” from the [qrs_template] are present in the the QRS. |
🟢 |
All 34 template variable spans present; repeated marker_#/qualitative_item_# rows expanded to 11 and 7 respectively. |
| 3.3 |
Spans that are not addressed in a checklist item are left unchanged |
🟢 |
Byte-identical to [qrs_template] outside the variable spans (CSS block and all non-variable body markup). |
| # |
Description |
Result |
Comments |
| 4.1 |
When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” |
N/A |
N/A — no source ER section is empty; every QRS-mapped ER section carries content. |
| 4.2 |
Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. |
🟢 |
|
| 4.3 |
Labels are not paraphrased, abbreviated, or invented. |
🟢 |
|
| 4.4 |
The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. |
🟢 |
|
| 4.5 |
The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. |
🟢 |
|
| # |
Description |
Result |
Comments |
| 5.1 |
The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. |
🟢 |
|
| 5.2 |
Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. |
🟢 |
|
| 5.3 |
The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. |
🟢 |
|
| 5.4 |
All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. |
🟢 |
|
| 5.5 |
The filename of the source ER is stated as “er_filename: [er_filename]” |
🟢 |
|
| 5.6 |
Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” |
🟢 |
|
| 5.7 |
Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) |
🟢 |
|
| 5.8 |
The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” |
🟢 |
|
| 5.9 |
The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) |
🟢 |
|
| 5.10 |
The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” |
🟢 |
|
| 5.11 |
The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) |
🟢 |
|
| 5.12 |
The filename of the document is stated as “qrs_filename: [filename of this document]” |
🟢 |
|
| 5.13 |
All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. |
🟢 |
|
| # |
Description |
Result |
Comments |
| 6.1 |
[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 |
|
| 6.2 |
[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 |
|
| 6.3 |
[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] |
🟢 |
|
| 6.4 |
[header_subline_model] is set to [qrs_creator_ai_fullname] |
🟢 |
|
| 6.5 |
No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. |
🟢 |
|
7. At-A-Glance Section
| # |
Description |
Result |
Comments |
| 7.1 |
[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 |
|
| 7.2 |
[at_a_glance] is no longer than 60 words |
🟢 |
59 words. |
| 7.3 |
Every fact in [at_a_glance] is supported by a distinct passage in the ER. |
🟢 |
|
| 7.4 |
It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead |
🟢 |
|
| 7.5 |
It DOES NOT cite specific trials (names, years, sample sizes, p-values) |
🟢 |
|
| 7.6 |
It DOES NOT cite effect sizes, relative risks, or statistical results |
🟢 |
|
8. Contraindications
| # |
Description |
Result |
Comments |
| 8.1 |
The section is derived from the ER Key Interactions & Contraindications section |
🟢 |
|
| 8.2 |
[stop_items] represent the Contraindications from the ER |
🟢 |
All 8 bullets of the ER “Populations who should avoid sodium citrate” list (ER lines 325-332) are represented. |
| 8.3 |
Individual [stop_items] are formatted as <li></li> |
🟢 |
|
| 8.4 |
Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. |
🟢 |
|
| 8.5 |
Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). |
🟢 |
|
| 8.6 |
When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. |
🟢 |
|
| 8.7 |
The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 |
|
| 8.8 |
If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. |
N/A |
N/A — the [stop_items] section is not empty (8 items). |
9. Key Interactions
| # |
Description |
Result |
Comments |
| 9.1 |
The section is derived from the ER Key Interactions & Contraindications section |
🟢 |
|
| 9.2 |
[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications |
🟢 |
All 9 remaining interaction bullets carried; the aluminium-antacid bullet (ER line 303) is correctly excluded as a contraindication. |
| 9.3 |
Individual [caution_items] are formatted as <li></li> |
🟢 |
|
| 9.4 |
Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. |
🟢 |
|
| 9.5 |
Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). |
🟢 |
|
| 9.6 |
When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. |
🟢 |
|
| 9.7 |
The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 |
|
| 9.8 |
If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. |
N/A |
N/A — the [caution_items] section is not empty (9 items). |
10. Protocol
| # |
Description |
Result |
Comments |
| 10.1 |
The section is derived from the ER Protocol section |
🟢 |
|
| 10.2 |
The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 |
|
| 10.3 |
If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. |
N/A |
N/A — the ER Therapeutic Protocol section supplies more than three actionable aspects; all three sets are used. |
| 10.4 |
All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 |
|
11. Time to Effect
| # |
Description |
Result |
Comments |
| 11.1 |
The three sets of [time] items cover the three most important time-to-effect aspects from the ER |
🟢 |
|
| 11.2 |
The sets are picked and ordered by the magnitude of the related benefit |
🟢 |
|
| 11.3 |
If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. |
N/A |
N/A — the ER supplies three distinct time-to-effect aspects; all three sets are used. |
| 11.4 |
All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. |
🟢 |
|
| 11.5 |
If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A |
N/A — the ER provides time-to-effect information (Practical Considerations, line 411). |
12. Benefits
| # |
Description |
Result |
Comments |
| 12.1 |
The section is derived from the ER Expected Benefits section |
🟢 |
|
| 12.2 |
Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] |
🟢 |
|
| 12.3 |
Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. |
🟢 |
|
| 12.4 |
Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. |
🟢 |
|
| 12.5 |
If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A |
N/A — all four benefit tiers carry items in the ER. |
13. Risks
| # |
Description |
Result |
Comments |
| 13.1 |
The section is derived from the ER Potential Risks & Side Effects section |
🟢 |
|
| 13.2 |
Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] |
🟢 |
|
| 13.3 |
Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. |
🟢 |
|
| 13.4 |
Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. |
🟢 |
|
| 13.5 |
If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. |
N/A |
N/A — all four risk tiers carry items in the ER. |
14. Monitoring
| # |
Description |
Result |
Comments |
| 14.1 |
The section is derived from the ER Monitoring section |
🟢 |
|
| 14.2 |
All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 |
All 11 biomarkers of the ER monitoring table (ER lines 441-451) are listed. |
| 14.3 |
[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 |
|
15. Qualitative Assessment
| # |
Description |
Result |
Comments |
| 15.1 |
The section is derived from the ER Monitoring section |
🟢 |
|
| 15.2 |
All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 |
All 7 qualitative markers (ER lines 455-461) are listed verbatim. |
Issues 27/08/2026 04:23
Pass rate 100.00%. No issues found.
Issues 27/08/2026 04:15
- 4.5 — Sheet overflows one A4 page: At the template’s 11pt/800px geometry the sheet renders to roughly 1.8–1.9 A4 pages; the header through Key Interactions block (lines 415-625) already fills the page, pushing Risks, the 11-row Monitoring table, the cadence line and the seven Qualitative items onto a second page, and the verbose fields were not condensed to the per-section budget.
- 2.8 — Time-to-Effect subs restate label and value: The three
time_#_sub cells (lines 503-506, 517-520, 531-534) repeat their own label and value rather than adding information, e.g. “Kidney-function and stone-recurrence endpoints take six months to several years to become visible.” under label “Kidney & stone endpoints” and value “6 months – several years”.
Fixes 27/08/2026 04:15
- 2.8 — Time-to-Effect subs de-duplicated: Rewrote all three
time_#_sub cells so they no longer restate their own label and value — “Kidney-function and stone-recurrence endpoints take six months to several years to become visible.” became “The outcome endpoints, and the slowest to move.”, “Urinary citrate and pH shift within 24–48 hours, and revert to baseline about 48 hours after the last dose.” became “Reverts to baseline about 48 hours after the last dose.”, and “Peaks 120–180 minutes after a single dose; sets the pre-exercise interval, which is individualised rather than fixed at 90 minutes.” became “Sets the pre-exercise interval, individualised rather than fixed at 90 minutes.”
- 4.5 — Protocol cells condensed: Trimmed the three
action_#_sub cells to the per-cell budget, e.g. “Sodium citrate and citric acid oral solution provides 1 mEq per mL, so 30–60 mL daily.” to “The oral solution provides 1 mEq per mL, so 30–60 mL daily.” and “A single dose by body mass, roughly ten times the daily alkalinizing dose; not a pattern anyone runs chronically.” to “Roughly ten times the daily alkalinizing dose; not run chronically.”
- 4.5 — Contraindication items shortened: Reduced the four longest stop items to one rendered line each while keeping every threshold and severity class — for example “Chronic kidney disease with eGFR below 30 mL/min/1.73 m² outside supervised nephrology care” became “eGFR below 30 mL/min/1.73 m² outside nephrology care”.
- 4.5 — Interaction item shortened: “Additive blood-pressure-modifying supplements (beetroot nitrate, potassium, magnesium, garlic extract, omega-3 fatty acids)” became “Blood-pressure-lowering supplements (beetroot nitrate, potassium, magnesium, garlic, omega-3)”, trimming the example list as permitted by 9.5.
Note on scope: the sheet remains longer than one A4 page after these edits. Sections 8.2, 9.2, 14.2 and 15.2 mandate carrying all 8 contraindications, all 9 interactions, all 11 biomarkers and all 7 qualitative markers from the ER, so the remaining length is driven by required content rather than by expandable prose; only prose condensation was available and it has been applied.